At its current price of approximately 2,991.0p (as of late May 2026), the Croda share price sits near the midpoint of its 52-week trading range of 2,427.0p to 3,312.0p. Following a challenging period of post-pandemic inventory destocking that dragged down the entire global speciality chemicals sector, Croda International Plc (LSE:CRDA) is executing a strong strategic turnaround. For investors seeking premium FTSE 100 constituents with high-barrier economic moats, analyzing the fundamental drivers behind the Croda share price is critical. This comprehensive guide dissects Croda’s financial health, segment-level performance, the pivotal 2026–2028 financial framework, dividend sustainability, and independent broker forecasts.

1. Fundamental Financial Health: Decoding the Latest Earnings Reports

When evaluating the croda share price, investors must look past superficial headlines. The company's full-year 2025 earnings report, published in February 2026, revealed a striking divergence between statutory and adjusted figures—a dynamic that frequently causes temporary market mispricing and presents opportunities for patient, long-term investors.

Statutory vs. Adjusted Performance

For the financial year ended December 31, 2025, Croda reported a 4.4% increase in statutory sales to £1,699.4 million, compared to £1,628.1 million in 2024. At constant currency, sales growth was an even more robust 6.6%, reaching £1,699.4 million. Despite this positive top-line growth, statutory profit before tax (PBT) plummeted by 56.2% to £91.0 million, down from £207.8 million in the previous year. Statutory basic earnings per share (EPS) declined by 60.9% to 44.4p.

This statutory contraction was driven by several key factors:

• Escalating Operating Costs: Total statutory operating costs rose 26% to £635.6 million, primarily driven by persistent global inflationary pressures and strategic growth investments.
• Transformation Program Expenses: Croda is executing a major restructuring and global optimization program. The short-term exceptional cash costs and asset write-downs associated with this initiative weighed heavily on statutory operating profit.
• Accounting Adjustments: One-off write-downs and adjustments under IFRS guidelines restricted GAAP earnings.

Conversely, Croda’s adjusted results paint a far more resilient picture of underlying profitability:

• Adjusted Profit Before Tax: Increased 8.4% to £276.2 million, comfortably beating the company-compiled analyst consensus of £267.8 million.
• EBITDA: Grew 7.1% at constant currency to £396.6 million, maintaining a strong EBITDA margin of 23.3%.
• Adjusted Operating Margin: Edged up to 17.4% (compared to 17.2% in FY24) as adjusted operating profit rose 7.9% at constant currency to £295.3 million.
• Adjusted Basic EPS: Rose 2.5% to 146.2p (up from 142.6p in FY24).

This performance demonstrates that while statutory figures have been temporarily suppressed by the costs of restructuring for future efficiency, Croda’s underlying cash-generating capability remains strong.

Q1 2026 Update: Market Stabilization

Supporting the recent recovery of the croda share price is the Q1 2026 sales update released in May 2026. Croda reported that first-quarter sales were entirely in line with expectations. On a constant-currency basis, Q1 2026 sales were similar to the prior-year period. Since Q1 2025 was an exceptionally strong comparator (featuring a 9% constant-currency sales spike), matching this baseline indicates that the destabilizing destocking phase has officially ended. Client inventory levels have returned to historic averages, building a solid fundamental floor for the LSE:CRDA ticker.

2. Core Business Segments: What Actually Moves the CRDA Ticker?

Croda operates a highly differentiated business model. Rather than competing in low-margin commodity chemicals, Croda focuses on highly specialized, low-inclusion ingredients that are functionally critical to its customers’ end products. Following the multi-billion-pound divestment of the majority of its industrial business to Cargill in 2022, the group consolidated its focus onto two primary research-intensive divisions: Consumer Care and Life Sciences.

Consumer Care: Premium Beauty and Active Peptides

The Consumer Care segment is Croda's largest business unit and a premier driver of its premium valuation. This segment includes Croda Beauty Actives, home care, and flavors & fragrances.

• FY25 Performance: Consumer Care grew sales by 8% in 2025, supported by the continued premiumization of the personal care market and the skinification trend, where consumers demand active, science-backed ingredients in cosmetic formulas.
• The Sederma Moat: Croda’s subsidiary, Sederma, is a world pioneer in peptide technology. Sederma’s proprietary Matrixyl range of anti-aging peptides is considered the gold standard in the beauty industry, formulated in over 1,500 skincare products globally.
• Pricing Power: Because active ingredients like Matrixyl represent a tiny fraction of a cosmetic product's total manufacturing cost but determine its physical efficacy, Croda possesses exceptional pricing power. This enables the division to pass on raw material inflation to global cosmetic giants, protecting corporate margins and supporting the croda share price.

Life Sciences: High-Tech Drug Delivery and Agriculture

The Life Sciences division is a high-tech powerhouse divided into pharma and crop protection.

• FY25 Performance: The segment registered an 8% sales expansion in 2025, marking a sharp recovery from the extreme destocking headwinds of late 2023 and 2024.
• Avanti Research and mRNA Delivery: In 2020, Croda acquired Avanti Polar Lipids, a knowledge-intensive pioneer in lipid-based drug delivery technologies. Today, operating under Avanti Research, this business is a critical supplier of the high-purity lipids and lipid nanoparticles (LNPs) required for advanced mRNA vaccines, gene editing, and oncological therapeutics. To support commercial scale-up, Croda opened a state-of-the-art 23,680-square-foot GMP lipids manufacturing facility in Lamar, Pennsylvania, in March 2025, significantly expanding its global manufacturing footprint alongside its Alabaster, Alabama, facility.
• Crop Protection (Crop Care): Croda supplies high-performance adjuvants that enhance the delivery and efficacy of crop protection chemicals. Following agricultural inventory normalization in 2025, Crop Care volumes have returned to organic growth trends, driven by the global imperative for agricultural yield optimization.

Industrial Specialties: The Circular Economy Sub-Segment

Following the major divestment to Cargill, the remaining Industrial Specialties segment exists primarily to process byproducts of the Consumer Care and Life Sciences divisions into eco-friendly industrial inputs.

• FY25 Performance: Sales in this minor segment fell 2%, which is aligned with management's strategic shift away from commodity chemical exposure.
• Role: This division helps Croda maintain its industry-leading ESG profile by maximizing raw material utilization, ensuring minimal waste, and generating highly sustainable circular products.

3. The 2026–2028 Financial Framework: Rebuilding Shareholder Value

To restore investor confidence and map out a clear path for future capital appreciation, CEO Steve Foots and the executive committee established a concrete three-year financial framework running through full-year 2028. This framework is a primary tool used by investment banks to calculate the forward croda share price forecast.

Path to Margin Expansion

To achieve the target adjusted operating margin of >20.0% by 2028 (up from 17.4% in 2025), Croda is capitalizing on years of heightened capital expenditure. The capital expenditure cycle is now normalizing back to historic averages of approximately 6% of sales, which will drastically improve free cash flow conversion. While depreciation is projected to increase by £10 million in 2026 as the final tranches of recent investments come online, the group's global transformation program is already yielding substantial administrative and operational cost savings. As manufacturing facilities achieve higher capacity utilization, operating leverage will naturally expand, driving earnings per share upward.

4. Croda Dividends: Evaluating Yield and Payout Safety

For income-oriented FTSE 100 investors, Croda's historical progressive dividend policy represents a key component of the total shareholder return profile.

Recent Dividend Metrics

For the financial year ended December 31, 2025, the Board proposed a total ordinary dividend of 111.0p per share, representing a 0.9% increase over the 110.0p distributed in 2024:

• Interim Dividend: 48.0p per share (paid on October 7, 2025).
• Final Dividend: 63.0p per share (ex-dividend date April 9, 2026; paid on May 27, 2026).
• Dividend Yield: Based on the trading price of ~2,991p, the dividend yield stands at a competitive 3.71%, significantly higher than the specialty chemicals sector's median yield of approximately 2.4%.

Is the Dividend Safe?

With adjusted basic EPS of 146.2p, the 111.0p dividend payout ratio sits at approximately 76%. This is notably above Croda’s long-term stated policy of keeping the payout ratio between 40% and 50% of adjusted earnings.

Despite this elevated payout ratio, the dividend remains secure for three principal reasons:

1. Strong Cash Generation: Croda generated £161.6 million in free cash flow in FY25, providing more than sufficient cash to cover the payout.
2. Deleveraging Balance Sheet: Net debt fell slightly to £523.8 million in 2025 (from £532.3 million in 2024), leaving the company with excellent leverage covenants and no near-term debt maturities of concern.
3. Board Confidence: The decision to raise the dividend, despite the payout ratio being temporarily above policy, is a strong signal of executive confidence in near-term organic earnings growth. As operating margins rise toward the 2028 target of >20%, EPS will expand and naturally drive the payout ratio back down into the 40–50% target band without requiring a dividend cut.

5. Croda Share Price Forecast: Bull vs. Bear Case and Broker Sentiment

To assess whether the croda share price is currently undervalued, we must evaluate the latest broker forecasts and the fundamental structural risks facing the business.

Analyst Consensus Target Prices

According to compiled research reports from Wall Street and city brokers, the average 12-month stock price target for Croda International is as follows:

• Median Price Target: 3,375.0p
• Average Price Target: 3,140.0p to 3,373.0p (depending on the analyst database used)
• High Forecast: 4,300.0p
• Low Forecast: 2,865.0p

With the share price currently trading at ~2,991p, the median analyst target of 3,375.0p represents a 12.8% potential upside. This consensus indicates that institutional investors view Croda as fundamentally undervalued at its current multiples.

The Bull Case: Catalysts for Outperformance

• Rapid Operational Efficiencies: If the global transformation program achieves its cost-saving objectives ahead of schedule, operating margins could exceed the 20% threshold before 2028, sparking rapid upward earnings revisions.
• Biologics and mRNA Boom: A surge in commercialized clinical trials utilizing Avanti's lipid delivery systems (LNPs) would dramatically scale up high-margin pharma volumes at the Lamar and Alabaster sites.
• Macroeconomic Rebound: A general global recovery in consumer spending would accelerate prestige beauty trends, increasing cosmetic formulation volumes within Consumer Care.
• Multiple Re-rating: Historically, due to its deep R&D moats, Croda has traded at a high-premium price-to-earnings multiple of 25x-30x. As earnings growth resumes, a return to these historical multiples would rapidly re-rate the stock back toward historical highs above 4,000p.

The Bear Case: Operational Risks

• Foreign Exchange Exposure: Since 65% of Croda’s sales are generated outside Europe (largely in USD and EUR), a strengthening British Pound (GBP) acts as a significant translation headwind. Management estimates a £1.0 million annualized impact on adjusted operating profit for every 1-cent movement in the USD or EUR exchange rate.
• Energy and Raw Material Inflation: Chemical processing requires energy. Any resurgence in global energy costs could compress gross margins if prices cannot be easily passed on to the lower-end industrial clients.
• Activist Shareholder Pressure: Some activist funds have highlighted Croda's temporary performance drop relative to peer chemical groups. While activist pressure can catalyze strategic clarity, it can also trigger near-term volatility, management distractions, and corporate overhead costs.

6. Frequently Asked Questions (FAQ)

What is Croda International's ticker symbol and where is it traded?

Croda International Plc is listed on the London Stock Exchange and trades under the ticker symbol LSE:CRDA. It is a constituent of the FTSE 100 index. International investors can also buy Croda through the US over-the-counter (OTC) markets under the ticker symbol COIHY.

Why did Croda's statutory profits drop in 2025 despite rising sales?

Statutory profit before tax fell by 56.2% due to a 26% increase in statutory operating costs, exceptional charges related to its global transformation program, non-cash asset write-downs, and pension-related adjustments under IFRS guidelines. Core profitability remains healthy, as shown by the 8.4% increase in adjusted profit before tax.

When is Croda's next dividend payment and what is the yield?

Croda’s next final dividend of 63.0p per share will be paid on May 27, 2026, to shareholders who held the stock before the ex-dividend date of April 9, 2026. Combined with the interim dividend of 48.0p, the full-year dividend is 111.0p, representing a competitive dividend yield of approximately 3.71%.

How does Avanti Polar Lipids fit into Croda's business?

Acquired by Croda in 2020 and now rebranded as Avanti Research, the subsidiary is a leading developer of high-purity lipids and lipid nanoparticles (LNPs). These lipids are critical drug delivery systems used in next-generation mRNA vaccines, gene therapies, and cancer treatments. Croda scaled up this high-tech IP with a new GMP-certified lipids facility in Lamar, Pennsylvania, in March 2025.

What is Sederma and why is it important to the Croda share price?

Sederma is Croda's premium beauty active subsidiary. It is globally recognized for inventing Matrixyl, the industry-leading anti-aging peptide used in over 1,500 skincare formulas worldwide. Sederma's high-margin, research-driven product portfolio gives Croda immense pricing power in the consumer care space, driving long-term earnings growth.

Conclusion: Weighing the Investment Case for Croda

In conclusion, the croda share price has established a firm floor as the global destocking cycle has run its course. While statutory reporting has been temporarily obscured by the necessary costs of corporate restructuring, the underlying fundamentals of Croda’s business units remain highly attractive.

With adjusted profit before tax growing by 8.4% in 2025, robust Q1 2026 sales in line with expectations, a secure 3.7% dividend yield, and a highly achievable 2026–2028 financial framework aimed at expanding operating margins above 20%, Croda represents an outstanding turnaround opportunity. For long-term investors looking to add a premier, research-driven FTSE 100 speciality chemicals leader with deep proprietary moats to their portfolio, Croda International (LSE:CRDA) offers a compelling blend of defensive yield and significant capital appreciation potential.